{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:55:56Z","timestamp":1794362156876,"version":"4.9.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"42","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007405","name":"Danish Heart Foundation","doi-asserted-by":"publisher","award":["18-R124-A8323-22091"],"award-info":[{"award-number":["18-R124-A8323-22091"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF18OC0034582"],"award-info":[{"award-number":["NNF18OC0034582"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health South-East research program in Norway","award":["2017205"],"award-info":[{"award-number":["2017205"]}]},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["302454"],"award-info":[{"award-number":["302454"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In patients with myocardial infarction (MI), no heart failure, and left ventricular ejection fraction (LVEF) \u2265 40%, the combined BETAMI-DANBLOCK trial showed that beta-blockers reduced the risk of all-cause mortality or major adverse cardiovascular events. This study evaluated the representativeness of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants in BETAMI (n = 2867) and DANBLOCK (n = 2707) were compared with a cohort of revascularized MI patients with LVEF \u226540%, and no heart failure from the Norwegian Myocardial Infarction Registry (the NORMI cohort)(n = 20 804). Baseline characteristics were evaluated, and absolute risks of all-cause mortality and\/or MI were estimated. A transportability analysis was conducted by weighting the BETAMI-DANBLOCK population according to the NORMI cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 66 years (interquartile range [IQR]: 57\u201374) in the NORMI cohort and 63 years (IQR: 55\u201370) in BETAMI and DANBLOCK. Patients in the NORMI cohort had a higher prevalence of diabetes, previous coronary artery disease, and LVEF 40\u201349%, compared with trial participants. At 3-year follow-up, the absolute risk of all-cause mortality or MI was 12.0% in the NORMI cohort, 7.7% in BETAMI, and 7.8% in DANBLOCK. Corresponding risks of MI were 6.3%, 5.6%, and 4.3%, respectively. The treatment effects of beta-blockers were similar when the trial population was weighted according to the characteristics of the NORMI cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with the NORMI cohort, participants in BETAMI and DANBLOCK were younger, had a lower proportion of certain comorbidities, and experienced a lower risk of all-cause mortality and MI. Despite these differences, the effect of beta-blockers remained consistent when the trial population was weighted according to the NORMI cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag348","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:20:48Z","timestamp":1776684048000},"page":"6300-6310","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-7902","authenticated-orcid":false,"given":"Anna Meta Dyrvig","family":"Kristensen","sequence":"first","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Bispebjerg and Frederiksberg , Nordre Fasanvej 57, 2000 Frederiksberg, Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarle","family":"Jortveit","sequence":"additional","affiliation":[{"name":"Department of Cardiology, S\u00f8rlandet Hospital Arendal , Arendal ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Holmager","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Bispebjerg and Frederiksberg , Nordre Fasanvej 57, 2000 Frederiksberg, Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8793","authenticated-orcid":false,"given":"Dan","family":"Atar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullevaal , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-8323","authenticated-orcid":false,"given":"Michael Hecht","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen, Denmark"},{"name":"Department of Internal Medicine, Holb\u00e6k Hospital , Holb\u00e6k ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnhild","family":"Bakken","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullevaal , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"Steigen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of North Norway and the Arctic University of Troms\u00f8 , Troms\u00f8 ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-3149","authenticated-orcid":false,"given":"Henrik","family":"Schirmer","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department of Cardiology, Akershus University Hospital , L\u00f8renskog ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-765X","authenticated-orcid":false,"given":"Thor","family":"Edvardsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alf Inge","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Stavanger University Hospital and University of Bergen , Stavanger ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Erik","family":"Otterstad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Vestfold Hospital Trust , Vestfold ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital\u2014Bispebjerg and Frederiksberg , Nordre Fasanvej 57, 2000 Frederiksberg, Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-2162","authenticated-orcid":false,"given":"John","family":"Munkhaugen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Drammen Hospital, Vestre Viken Hospital Trust , Drammen ,","place":["Norway"]},{"name":"Department of Behavioural Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ullevaal , Oslo ,","place":["Norway"]},{"name":"Institute of Clinical Medicine, Faculty of Medicine, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2026111008083456300_ehag348-B1","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"2026111008083456300_ehag348-B2","first-page":"I26","article-title":"The G\u00f6teborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction","volume":"67","author":"Hjalmarson","year":"1983","journal-title":"Circulation"},{"key":"2026111008083456300_ehag348-B3","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group","volume":"2","author":"ISIS-1 Collaborative Group","year":"1986","journal-title":"Lancet Lond Engl"},{"key":"2026111008083456300_ehag348-B4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1161\/01.CIR.66.6.1179","article-title":"Timolol-related reduction in mortality and reinfarction in patients ages 65\u201375 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group","volume":"66","author":"Gundersen","year":"1982","journal-title":"Circulation"},{"key":"2026111008083456300_ehag348-B5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/ehjcvp\/pvad093","article-title":"The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: design, rationale, and baseline characteristics","volume":"10","author":"Kristensen","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026111008083456300_ehag348-B8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","volume":"393","author":"Munkhaugen","year":"2025","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B9","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard\u2013lessons from the history of RCTs","volume":"374","author":"Bothwell","year":"2016","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u2018to whom do the results of this trial apply?","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet Lond Engl"},{"key":"2026111008083456300_ehag348-B11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making\u2014beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B12","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.4045\/tidsskr.14.0804","article-title":"Myocardial infarction in Norway in 2013","volume":"134","author":"Jortveit","year":"2014","journal-title":"Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke"},{"key":"2026111008083456300_ehag348-B13","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.23.0821","article-title":"Data quality in the Norwegian myocardial infarction registry","volume":"144","author":"Kiel","year":"2024","journal-title":"Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke"},{"key":"2026111008083456300_ehag348-B14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2147\/CLEP.S105933","article-title":"Interrater reliability of a national acute myocardial infarction register","volume":"8","author":"Govatsmark","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2026111008083456300_ehag348-B15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/CLEP.S321293","article-title":"Validating acute myocardial infarction diagnoses in national health registers for use as endpoint in research: the Troms\u00f8 study","volume":"13","author":"Varmdal","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2026111008083456300_ehag348-B16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/aje\/kwx164","article-title":"Transportability of trial results using inverse odds of sampling weights","volume":"186","author":"Westreich","year":"2017","journal-title":"Am J Epidemiol"},{"key":"2026111008083456300_ehag348-B17","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026111008083456300_ehag348-B18","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026111008083456300_ehag348-B19","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1111\/j.1532-5415.2010.03032.x","article-title":"Fighting against age discrimination in clinical trials","volume":"58","author":"Cherubini","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"2026111008083456300_ehag348-B20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"2026111008083456300_ehag348-B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10654-024-01119-3","article-title":"Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial","volume":"39","author":"Matthews","year":"2024","journal-title":"Eur J Epidemiol"},{"key":"2026111008083456300_ehag348-B22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa2404204","article-title":"Beta-blocker interruption or continuation after myocardial infarction","volume":"391","author":"Silvain","year":"2024","journal-title":"N Engl J Med"},{"key":"2026111008083456300_ehag348-B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"2026111008083456300_ehag348-B24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"\u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","volume":"406","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"2026111008083456300_ehag348-B25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen","year":"2026","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/42\/6300\/68381699\/ehag348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/42\/6300\/68381699\/ehag348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:08:39Z","timestamp":1794316119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/42\/6300\/8692711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":25,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2026,5,25]]},"published-print":{"date-parts":[[2026,11,10]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag348","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,7]]},"published":{"date-parts":[[2026,5,25]]}}}